These authors contributed equally to this work.
Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery
Article first published online: 24 SEP 2012
© 2012 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 36, Issue 10, pages 922–928, November 2012
How to Cite
Yang, Z., Wu, Q., Wang, F., Wu, K. and Fan, D. (2012), Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Alimentary Pharmacology & Therapeutics, 36: 922–928. doi: 10.1111/apt.12060
As part of AP&T's peer-review process, a technical check of this meta-analysis was performed by Dr P. Collins.
- Issue published online: 16 OCT 2012
- Article first published online: 24 SEP 2012
- Manuscript Accepted: 9 SEP 2012
- Manuscript Revised: 7 SEP 2012
- Manuscript Revised: 6 APR 2012
- Manuscript Received: 21 MAR 2012
- National Natural Science Foundation of China. Grant Numbers: 81172062, 81000988
Infliximab is widely used in severe and refractory ulcerative colitis (UC). The results of clinical studies are inconsistent on whether preoperative infliximab use increases early postoperative complications in UC patients.
To determine the clinical safety and efficacy of preoperative infliximab treatment in UC patients with regard to short-term outcomes following abdominal surgery.
PubMed, Embase databases were searched for controlled observational studies comparing postsurgical morbidity in UC patients receiving infliximab preoperatively with those not on infliximab. The primary endpoint was total complication rate. Secondary endpoints included the rate of infectious and non-infectious complications. We calculated pooled odds ratios (ORs) with 95% confidence intervals (CIs) as summary measures.
A total of 13 studies involving 2933 patients were included in our meta-analysis. There was no significant association between infliximab therapy preoperatively and total (OR = 1.09, 95% CI: 0.87–1.37, P = 0.47), infectious (OR = 1.10, 95% CI: 0.51–2.38, P = 0.81) and non-infectious (OR = 1.10, 95% CI: 0.76–1.59, P = 0.61) postoperative complications respectively. Infliximab might be a protective factor against infection for the use within 12 weeks prior to surgery (OR = 0.43, 95% CI: 0.22–0.83, P = 0.01). No publication bias was found.
Preoperative infliximab use does not increase the risk of early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery.